All In Biotech

Free tool

FAERS Monitor: Qbrexza

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 210361 or its brand name (Qbrexza, Glycopyrronium Tosylate). Reports on generic versions are filed under their own applications.

Reports

1,551

Serious

788

51% of reports

Hospitalization

414

Death reported

99

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • mydriasis273
  • dry mouth241
  • off label use195
  • vision blurred188
  • drug ineffective97
  • intentional product misuse94
  • urinary retention89
  • headache85
  • constipation72
  • dyspnoea69
  • pneumonia59
  • nausea54
  • wrong technique in product usage process54
  • hyperhidrosis51
  • oropharyngeal pain51

Reports by year received

View as table
YearReports
20083
20093
20103
20112
20125
20136
20148
201517
201637
201739
201857
2019491
2020226
2021170
202289
2023106
2024121
2025103
202665

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,608 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
mydriasisSignal273294.8264.377,989
dry mouthSignal24140.436.09,229
urinary retentionSignal8936.329.63,014
vision blurredSignal18818.616.33,128
intentional product misuseSignal9414.612.01,179
oropharyngeal painSignal517.55.7281
hyperhidrosisSignal515.44.1178
constipationSignal724.53.6193
wrong technique in product usage processSignal543.62.8100
off label useSignal1953.02.6273
pneumoniaSignal592.51.951
headache851.81.533
dyspnoea691.71.318
drug ineffective971.00.80
nausea540.90.70

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.